TAMOXIFEN, AMINOGLUTETHIMIDE AND DANAZOL - EFFECT OF THERAPY ON HORMONES IN POST-MENOPAUSAL PATIENTS WITH BREAST-CANCER
Dexamethasone, prostaglandin A, and retinoic acid modulation of murine and human melanoma cells grown in soft agar.
The cloning efficiencies of a murine melanoma cell line (S91 CCL 53.1) and a human melanoma cell strain (C8146c) were inhibited by dexamethasone (DEX), prostaglandin A1 (PGA1), and beta-all-trans-retinoic acid (RA) in a dose-dependent manner. Murine melanoma tumor colony-forming units (MTCFU) were inhibited more than 99% by DEX (1 X 10(-7) M) and R...
Dexamethasone, prostaglandin A, and retinoic acid modulation of murine and human melanoma cells grown in soft agar.
The cloning efficiencies of a murine melanoma cell line (S91 CCL 53.1) and a human melanoma cell strain (C8146c) were inhibited by dexamethasone (DEX), prostaglandin A1 (PGA1), and beta-all-trans-retinoic acid (RA) in a dose-dependent manner. Murine melanoma tumor colony-forming units (MTCFU) were inhibited more than 99% by DEX (1 X 10(-7) M) and R...
Dexamethasone, prostaglandin A, and retinoic acid modulation of murine and human melanoma cells grown in soft agar.
The cloning efficiencies of a murine melanoma cell line (S91 CCL 53.1) and a human melanoma cell strain (C8146c) were inhibited by dexamethasone (DEX), prostaglandin A1 (PGA1), and beta-all-trans-retinoic acid (RA) in a dose-dependent manner. Murine melanoma tumor colony-forming units (MTCFU) were inhibited more than 99% by DEX (1 X 10(-7) M) and R...
Effects on metastases of drug therapy during developing and established tumor immunity
The effectiveness of treatment with cyclophosphamide, methotrexate and 5-fluorouracil was studied during the s.c. and pulmonary growth of syngeneic C3H/He mammary carcinomas. Treatments with cyclophosphamide, methotrexate and 5-fluorouracil during the primary induction of immunity against a mouse mammary carcinoma inhibited the growth of the tumor,...
尿路1生器腫瘍に対するUFTの臨床成績 / Clinical effect of UFT on urogenital tumors
UFTを腎細胞癌7例, 膀胱癌5例, 前立腺癌4例に投与した.1)抗腫瘍効果は, complete response (CR) 2例, partial response (PR) 2例, NC 12例で, PDはみとめず, 有効率は16例中4例であった.2)腎細胞癌では7例中CR 1例, PR 1例, 膀胱癌では5例中CR 1例, PR 1例であったが, 前立腺癌4例はすべてNCであった.3)副作用は, 600 mg/日投与6例中3例に, それぞれ食欲不振, 嘔気と嘔吐, 口内炎をみたが, 300 mg/日投与例に消化器症状はみなかった.4)骨髄機能の抑制や, 肝, 腎機能障害はみなかった / Clinical study of UFT which was a mixture of FT a...
Adjuvant chemotherapy. Eight years later
Doxorubicin and cisplatin excretion into human milk
Plasma and milk concentrations of doxorubicin (DOX) and cisplatin were measured after iv administration of these agents to a lactating patient with ovarian cancer. Cisplatin was undetectable in human milk. Milk concentrations of DOX often exceeded those detected in concomitant plasma samples. For DOX, the highest milk:plasma concentration ratio was...
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated pati...
In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for A...
A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: An ECOG study
Of 86 patients entered in an Eastern Cooperative Oncology Group (ECOG) random Phase II study of mitoxantrone (DHAD) and cisplatin (DDP) in primary liver cancer, 69 were eligible. Nine of the 13 ineligible patients were excluded after a pathology review. Sixty‐one percent of the patients were North American, and 39% were South African. The most comm...
